stockportfolio.pro
IDEXX Laboratories, Inc. (IDXX)
Healthcare · Diagnostics & Research · NasdaqGS
IDEXX Laboratories, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.78B | $1.97B | $2.21B | $2.41B | $2.71B | $3.22B | $3.37B | $3.66B | $3.90B | $4.30B |
| Gross profit | $975.44M | $1.10B | $1.24B | $1.37B | $1.57B | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B |
| Net income | $222.04M | $263.14M | $377.03M | $427.72M | $581.78M | $744.85M | $679.09M | $845.04M | $887.87M | $1.06B |
| Net margin | 12.5% | 13.4% | 17.0% | 17.8% | 21.5% | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
Source: IDEXX Laboratories, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into IDXX stock?
At today's market cap of $45.66B, IDEXX Laboratories, Inc. is priced for free-cash-flow growth of about 18.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.06B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 14.3%/yr over the last five fiscal years and revenue 9.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of IDEXX Laboratories, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IDXX in your portfolio →
IDEXX Laboratories, Inc. financial history by metric
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
IDEXX Laboratories, Inc. — frequently asked questions
What is IDEXX Laboratories, Inc.'s revenue?
IDEXX Laboratories, Inc. (IDXX) reported revenue of $4.30B for fiscal year 2025, up 10.4% from the prior year, according to its SEC filings.
Is IDEXX Laboratories, Inc. profitable?
Yes. IDXX earned net income of $1.06B in fiscal 2025, a net margin of 24.6%.
What is IDXX's P/E ratio?
IDEXX Laboratories, Inc. trades at a price-to-earnings ratio of about 42.6 based on the latest data in our nightly-refreshed cache.
How fast is IDEXX Laboratories, Inc. growing?
IDXX's revenue grew at roughly 9.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does IDEXX Laboratories, Inc. have?
As of fiscal year 2025, IDXX carried roughly $450.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is IDEXX Laboratories, Inc.'s gross margin?
IDXX's gross margin was 61.8% in fiscal 2025 — gross profit of $2.66B on revenue of $4.30B.
What is IDEXX Laboratories, Inc.'s market cap?
IDEXX Laboratories, Inc. (IDXX) has a market capitalization of about $45.66B, based on the latest data in our nightly-refreshed cache.
When does IDEXX Laboratories, Inc.'s fiscal year end?
IDXX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into IDXX stock?
At today's market cap of $45.66B, IDEXX Laboratories, Inc. is priced for free-cash-flow growth of about 18.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.06B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 14.3%/yr over the last five fiscal years and revenue 9.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from IDEXX Laboratories, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.